These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10954961)

  • 1. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
    Ball P
    Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving care for patients with respiratory tract infections.
    Lode H; Garau J
    J Chemother; 2002 Feb; 14 Suppl 2():22-8. PubMed ID: 12003137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
    DeAbate CA; Mathew CP; Warner JH; Heyd A; Church D
    Respir Med; 2000 Nov; 94(11):1029-37. PubMed ID: 11127487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
    Dalhoff A; Krasemann C; Wegener S; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.
    Balfour JA; Lamb HM
    Drugs; 2000 Jan; 59(1):115-39. PubMed ID: 10718103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moxifloxacin (Avelox) for the treatment of bacterial skin infections.
    Parish LC; Witkowski JA; Routh HB
    Skin Therapy Lett; 2001 Oct; 6(11):1-2. PubMed ID: 11719825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin.
    Landen H; Möller M; Tillotson GS; Kubin R; Höffken G
    J Int Med Res; 2001; 29(2):51-60. PubMed ID: 11393349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin: clinical efficacy and safety.
    Culley CM; Lacy MK; Klutman N; Edwards B
    Am J Health Syst Pharm; 2001 Mar; 58(5):379-88. PubMed ID: 11258173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
    Wispelwey B; Schafer KR
    Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxifloxacin: a respiratory fluoroquinolone.
    Miravitlles M; Anzueto A
    Expert Opin Pharmacother; 2008 Jul; 9(10):1755-72. PubMed ID: 18570608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin.
    Simoens S; Decramer M
    Expert Opin Pharmacother; 2008 Jul; 9(10):1735-44. PubMed ID: 18570606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
    Miravitlles M; Ros F; Cobos A; Kubin R; Tillotson G
    Int J Clin Pract; 2001 Sep; 55(7):437-41. PubMed ID: 11594251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.
    Yoo BK; Triller DM; Yong CS; Lodise TP
    Ann Pharmacother; 2004; 38(7-8):1226-35. PubMed ID: 15187209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations.
    Iannini PB
    Curr Med Res Opin; 2007 Jun; 23(6):1403-13. PubMed ID: 17559736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moxifloxacin: a review of its use in the management of bacterial infections.
    Keating GM; Scott LJ
    Drugs; 2004; 64(20):2347-77. PubMed ID: 15456331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group.
    Patel T; Pearl J; Williams J; Haverstock D; Church D
    Respir Med; 2000 Feb; 94(2):97-105. PubMed ID: 10714413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.